latest news in companies

Walmart to Replace AstraZeneca in Strategic Nasdaq-100 Index Update

Walmart to Replace AstraZeneca in Strategic Nasdaq-100 Index Update

New York, Saturday, 10 January 2026.
Replacing AstraZeneca on January 20, Walmart enters the tech-heavy Nasdaq-100, validating its digital transformation as the retailer approaches a historic $1 trillion valuation.

LuxUrban Report Separates Corporate Liabilities From Founder's Personal Finances

LuxUrban Report Separates Corporate Liabilities From Founder's Personal Finances

San Francisco, Sunday, 11 January 2026.
New filings argue LuxUrban’s financial collapse stems from systemic corporate risks, attempting to distinguish business exposure from the founder’s personal finances despite $98 million in guarantees.

Corcept Therapeutics Faces Market Selloff and Legal Probes Following FDA Rejection of Relacorilant

Corcept Therapeutics Faces Market Selloff and Legal Probes Following FDA Rejection of Relacorilant

San Francisco, Friday, 9 January 2026.
Corcept Therapeutics (NASDAQ: CORT) is under intense pressure after the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, a treatment for hypertension caused by hypercortisolism. The regulatory rejection, announced on December 31, 2025, precipitated a massive 50% collapse in share value, effectively erasing $3.6 billion in market capitalization. While the FDA acknowledged some positive trial data, it concluded that additional evidence is required to establish the drug’s effectiveness. Consequently, the company now faces a wave of investigations from shareholder rights law firms, including Hagens Berman and Scott+Scott. These inquiries focus on whether management overstated relacorilant’s clinical efficacy and the commercial prospects of its hypercortisolism business to investors. Analysts have subsequently downgraded price targets, casting doubt on Corcept’s ability to meet its projected revenue goals within the previously stated timeframe.

China SXT Pharmaceuticals Raises $10 Million Selling Shares at Significant Discount

China SXT Pharmaceuticals Raises $10 Million Selling Shares at Significant Discount

Taizhou, Friday, 9 January 2026.
China SXT secures $10 million by selling shares at just $0.15 to a single investor, a move following their strategic AI pivot that triggered significant market volatility today.

Apogee Enterprises Under Investigation After Stock Plunges Seventeen Percent

Apogee Enterprises Under Investigation After Stock Plunges Seventeen Percent

San Diego, Friday, 9 January 2026.
Apogee Enterprises faces a federal securities investigation after its stock plummeted 17% on January 7, 2026. The sharp decline coincided with missed revenue targets and the sudden resignation of CFO Matthew Osberg.

Aquestive Therapeutics Faces Legal Scrutiny After FDA Flags Deficiencies in Anaphylm Application

Aquestive Therapeutics Faces Legal Scrutiny After FDA Flags Deficiencies in Anaphylm Application

Atlanta, Friday, 9 January 2026.
Aquestive Therapeutics is under investigation for potential securities violations following a nearly 40% stock plunge on January 9, 2026. The sharp decline occurred after the FDA identified deficiencies in the application for Anaphylm, the company’s severe allergy treatment, effectively stalling labeling discussions. With the critical January 31 approval deadline looming, multiple law firms are now examining whether the company misled investors regarding the drug’s regulatory viability.

Sprouts Farmers Market Shareholders Face Upcoming Deadline in Securities Fraud Lawsuit

Sprouts Farmers Market Shareholders Face Upcoming Deadline in Securities Fraud Lawsuit

Los Angeles, Friday, 9 January 2026.
Following a massive 26% stock decline, shareholders must file by January 26, 2026, to lead the lawsuit claiming Sprouts concealed slowing growth and weak consumer resilience.

AMC Stock Hits Record Lows Despite Best Holiday Box Office Since 2021

AMC Stock Hits Record Lows Despite Best Holiday Box Office Since 2021

Leawood, Friday, 9 January 2026.
Shares touched historic lows near $1.45, defying an operational resurgence that included hosting Netflix’s Stranger Things finale and achieving its best pre-Christmas box office revenue since 2021.

Lawsuit Alleges EmblemHealth Blocked Mental Health Access Through Inaccurate Directories

Lawsuit Alleges EmblemHealth Blocked Mental Health Access Through Inaccurate Directories

New York, Friday, 9 January 2026.
The complaint accuses the insurer of inflating networks with unavailable providers—listing one psychiatrist 29 times—effectively denying New York City employees access to covered mental health treatment.

Ondas Holdings Secures $1 Billion Investment Priced Above Market Value

Ondas Holdings Secures $1 Billion Investment Priced Above Market Value

New York, Friday, 9 January 2026.
Ondas successfully priced a $1 billion offering at a 17.5% premium, a rare liquidity event signaling exceptional confidence in its autonomous systems strategy.